Clinical Trials on Same-day Discharge in Russian Federation

Total 11 results

Allergan

Completed

An Observational Study of Dry Eye Prior to Laser-Assisted in Situ Keratomileusis (LASIK) Therapy

Dry Eye Syndromes

Russian Federation
Pirogov Russian National Research Medical University

Completed

The Efficacy and Safety of Interventions on the Pelvic Veins in Pelvic Venous Disorders (ESIPV)

May-Thurner Syndrome | Pelvic Congestive Syndrome | Pelvic Venous Disorders

Russian Federation
Allergan

Completed

A Study to Compare the Safety and Efficacy of A New Eye Drop Formulation With OPTIVE™ in Subjects With Dry Eye Disease

Dry Eye Disease

France, Spain, Russian Federation, Belgium, Germany, Italy, United Kingdom, Australia
Santen SAS

Completed

3-year Study in Dry Eye Disease Patients With Severe Keratitis Receiving Ikervis® (1mg/mL Ciclosporin)

Dry Eye Disease With Severe Keratitis

Czechia, France, Italy, Poland, Russian Federation, Spain, Turkey
TearLab Corporation
Abbott Medical Optics; TLC Laser Eye Center

Completed

TearLab Refractive Surgery Dry Eye Study

Dry Eye Syndromes

United States
Antisoma Research

Unknown

Phase III Randomized Study of Amonafide (AS1413) and Cytarabine Versus Daunorubicin and Cytarabine in Patients With Secondary Acute Myeloid Leukemia (AML)- the ACCEDE Study

Secondary Acute Myeloid Leukemia (Secondary AML, sAML)

Korea, Republic of, United States, Spain, United Kingdom, Australia, Austria, Taiwan, Israel, Italy, Belgium, Germany, France, Romania, Estonia, Canada, Ukraine, Ecuador, Hungary, Poland, Chile, Argentina, Czech Republic, Russian Federation
Genzyme, a Sanofi Company

Active, not recruiting

A Multinational, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Pharmacodynamics, Pharmacokinetics, and Safety of Venglustat in Late-onset GM2 (AMETHIST)

Tay-Sachs Disease | Sandhoff Disease

United States, Argentina, Czechia, Portugal, Russian Federation, Turkey, United Kingdom, Brazil, France, Germany, Italy, Japan, Spain
Bristol-Myers Squibb

Terminated

Proof of Concept Study to Evaluate the Efficacy and Safety of BMS-931699 (Lulizumab) or BMS-986142 in Primary Sjögren's Syndrome

Sjögren's Syndrome

Australia, United States, Italy, Mexico, Colombia, Peru, Puerto Rico, South Africa, Chile, Poland, Russian Federation
Novartis Pharmaceuticals

Completed

Safety and Efficacy of VAY736 in Patients With Primary Sjogren's Syndrome (pSS)

Primary Sjogren Syndrome

United States, Belgium, Italy, Austria, Israel, France, Germany, Hungary, Netherlands, United Kingdom, Japan, Portugal, Argentina, Spain, Taiwan, Russian Federation, Romania, Chile, Poland
Novartis Pharmaceuticals

Active, not recruiting

Study of Safety and Tolerability of CFZ533 in Patients With Sjögren's Syndrome (TWINSS Extn)

Sjogren's Syndrome

United Kingdom, Netherlands, Australia, Austria, Israel, France, Germany, Greece, Hungary, Italy, United States, Korea, Republic of, Japan, Portugal, Russian Federation, Turkey, Colombia, Romania, Argentina, Chile, Brazil, Canada, S...
Novartis Pharmaceuticals

Completed

Study of Safety and Efficacy of Multiple Doses of CFZ533 in Two Distinct Populations of Patients With Sjogren's Syndrome (TWINSS)

Sjögren Syndrome

United States, United Kingdom, Netherlands, Australia, Austria, Israel, France, Germany, Greece, Hungary, Italy, Korea, Republic of, Japan, Portugal, Russian Federation, Turkey, Canada, Colombia, Romania, Argentina, Chile, Brazil, S...

Clinical Trials on Same-day Discharge in Russian Federation

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Israel

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations